NHF's MASAC issues two new documents, one on treatment recommendations and the other on physical therapy guidelines.
FDA approves Baxalta's Vonvendi, the first recombinant von Willebrand factor therapy for patients with VWD.
Rice University researchers confirm the presence of factor VIII in endothelial cells, a potential site for future gene therapy.
NHF and HTCs respond to HRSA's proposed guidance changes on 340B Drug Pricing Program.
NHF and CDC work together to improve inhibitor screening and testing, after data show true prevalence among people with hemophilia.
NHF chapters hit the ball out of the park with a winning 2015 Walk season, raising money and awareness for the bleeding disorders community.
Alnylam Pharmaceuticals announces Phase 1 study of ALN-AT3, a subcutaneous therapy being tested on patients with hemophilia.
HTRS announces two new clinical fellowship awards in 2016 for MDs or DOs interested in focusing on hemophilia and/or other rare bleeding disorders.
FDA approves Baxalta's ADYNOVATE, a new longer- lasting recombinant factor VIII product for people with hemophilia A.
Study suggests that toddlers first treated with recombinant factor product are more likely to develop an inhibitor.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car